Background {#Sec1}
==========

Prostate cancer (PCa) and type 2 Diabetes Mellitus (T2DM) are prevalent conditions that often occur concomitantly \[[@CR1]\]. Pre-existing T2DM has been associated with a decreased risk of PCa in multiple observational studies \[[@CR2]--[@CR8]\]. Existing studies examining the association of antidiabetic medications with PCa risk have, however, produced inconsistent results. While some suggest an inverse association of antidiabetic medications, particularly metformin, with PCa risk \[[@CR9]--[@CR13]\], others suggest null associations \[[@CR14]--[@CR17]\]. These existing studies have not explored the effect of the duration of antidiabetic medications on PCa risk. Moreover, few studies have assessed the impact of antidiabetic medications on severity of PCa at the time of diagnosis, i.e. PCa risk categories.

In a previous study using Prostate Cancer data Base Sweden (PCBaSe) and the National Diabetes Register data, Fall et al. (2013) reported reduced risk of PCa across all PCa risk categories (OR = 0.80, 95%CI = 0.76--0.86) for men with T2DM compared to men without T2DM, especially low-risk PCa (OR = 0.71, 95%CI = 0.64--0.80) \[[@CR4]\]. Since 2013, the National Diabetes Register have improved completeness of their data. In addition, PCBaSe has now been linked to the National Prescribed Drug Register to assess what medications patients receive for T2DM. Here, we use updated PCBaSe data to examine the association between duration of T2DM and antidiabetic medications and PCa risk.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

We conducted a case-control study using PCBaSe 4.1 which is based on the National Prostate Cancer Register (NPCR) of Sweden, a nationwide population-based register starting in 1998 that includes more than 98% of the men registered with PCa in the National Cancer Register. NPCR contains detailed data on cancer characteristics including prostate-specific antigen (PSA) at the time of diagnosis, staging and Gleason Grade Groups \[[@CR18]\]. Using the unique personal identity number given to all residents in Sweden, all participants have been subsequently linked to Swedish health care registers and demographic databases. These include the National Patient Register and Longitudinal integrated database for health insurance and labour market studies, to obtain data on co-morbidities, civil status and educational level in 2008 \[[@CR18]\]. Comorbidities were quantified using the Charlson Comorbidity Index (CCI), based on discharge diagnoses in the In-Patient Registry with different weights (1, 2, 3 and 6) to each ICD code \[[@CR19], [@CR20]\]. For the current study, diabetes was not included in the CCI.

For every case in PCBaSe, five PCa-free control men (*n* = 154,812) were randomly selected from the general Swedish population by use of the personal identity number \[[@CR21]\], matched on year of birth and county of residence. The National Diabetes Register was initiated in 1996, and data records were linked via the personal identity number to PCBaSe \[[@CR1]\]. In 2013, approximately 92% of the prevalent cases of type 1 and type 2 diabetes mellitus were included in the National Diabetes Register. We also used data from the National Prescribed Drug Register. The National Prescribed Drug Register was established in July 2005 and contains all prescribed drugs dispensed at pharmacies in Sweden.

Identification of men with T2DM {#Sec4}
-------------------------------

To investigate the association between T2DM and PCa, we assessed data related to T2DM diagnosis and drug treatments available in the National Diabetes Register and National Prescribed Drug Register. We defined pre-existing T2DM as fulfilling at least one of following criteria: a medical record of the year of T2DM onset in the National Diabetes Registera registration date of T2DM in the National Diabetes Registera prescription for antidiabetic drugs (at least two filled prescriptions records) in the National Prescribed Drug Register.

Exposure {#Sec5}
--------

The primary exposure was duration of T2DM. The duration of T2DM was calculated using the year of T2DM onset or the registration date of T2DM in the National Diabetes Register (94%), or the duration of antidiabetic medications in the National Prescribed Drug Register (6%).

In addition, we also used duration of antidiabetic medications, including insulin, metformin, and sulphonylurea (SU) as documented in the National Prescribed Drug Register up to 8.5 years prior to the date of PCa diagnosis (July 2005 -- December 2016). As the Swedish drug reimbursement system is based on records of patients' visiting to the pharmacies every 3 months, the 8.5-year period in the National Prescribe Drug Register was divided into 34 sub-periods, which were shown as 34 filled prescription records in the dataset of the study. Each filled prescription record equates to 3 months' antidiabetic medication. Men with at least two filled prescription records of the same antidiabetic medication were assumed to be taking that antidiabetic drug as a treatment of T2DM. The duration of an antidiabetic drug was defined by the number of the corresponding records found in the National Prescribed Drug Register.

Use of metformin was divided into high-dose and low-dose groups with a cut-off at 1 g of metformin per day. We categorized duration into 3 groups: (i) ≥0.5 year - \< 3 years, (ii) ≥3 year - \< 5 years, and (iii) 5 year - ≤8.5 years. We calculated duration of insulin, metformin, and SU separately, even if some men received more than one antidiabetic drug. For example, if a man took high-dose metformin and insulin at the same time, he contributed time to the duration of both high-dose metformin and insulin.

Outcome {#Sec6}
-------

The primary outcome of the study was diagnosis of PCa, and we also obtained information on PCa risk categories from the NPCR. According to the modified version of the National Comprehensive Cancer Network (NCCN) guideline, men with PCa can be categorized into five risk categories: i) low-risk: T1 or T2a stage, PSA \< 10 ng/mL and Gleason score 6; ii) intermediate-risk: T2b or T2c stage, 10 ng/mL, PSA \< 20 ng/mL, or Gleason score 7; iii) high-risk: T3a or T4 stage, PSA ≥ 20 ng/mL, or Gleason score ≥ 8; iv) regional metastases any T, N1 and M0 stage; v) distant metastases, any T or N and M1 stage \[[@CR22]\]. In the main analysis, we included men with high-risk, regional metastases, and distant metastases into the high-risk category group to increase the power. We also conducted a subgroup analysis for each category.

Statistical analysis {#Sec7}
--------------------

Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for PCa risk. Models were adjusted for education levels (high, middle and low), civil status (married, not married, widowed and divorced), CCI and age at the year of PCa diagnosis.

All data management was performed with STATA 15.1. The study has been approved by The Research Ethics Board at Uppsala University, Sweden.

Results {#Sec8}
=======

31,415 men with PCa and 154,812 PCa-free men were included in the study. Table [1](#Tab1){ref-type="table"} shows their baseline characteristics. Of the men with PCa, 4186 (13%) had T2DM, whereas among the controls 24,965 (16%) had T2DM. Age, education level, civil status and CCI were similar for cases and controls (Table [1](#Tab1){ref-type="table"}). PCa men with T2DM were more likely to be diagnosed with advanced PCa or metastatic disease and had higher PSA and Gleason grade group 4 & 5 compared with PCa men without T2DM, as shown in Table [2](#Tab2){ref-type="table"}. Table 1Characteristics of men in PCBaSe 4.1 diagnosed with prostate cancer between 2014 and 2016 (*n* = 31,415) and their matched controls (*n* = 154,812)Controls, ***N*** = 154,812Cases, ***N*** = 31,415***N***%***N***%**Age (year),*n*(%)**  \< 5016171.03261.0 50--5917,80611.5362511.5 60--6961,28739.612,51439.8 70--7954,06234.910,90034.7 80+20,04012.9405012.9**Education level,*n*(%)** Low48,88231.6931129.6 Middle79,90451.616,55352.7 High24,15915.6534817.0 Missing18,671.22030.6**Civil status,*n*(%)** Married92,57659.820,12264.1 Not married24,43115.8412013.1 Divorced26,64717.2494615.7 Widower11,1517.222167.1 Missing70.0110.0**CCI,*n*(%)** 0113,60273.423,61675.2 120,10213.0373411.9 212,0327.825018.0 3+90765.915625.0Numbers may not add up to 100% due to rounding*Abbreviations*: *N* number, *CCI* Charlson Comorbidity IndexTable 2Characteristics of men in PCBaSe 4.1 diagnosed with prostate cancer between 2014 by T2DM statusNo T2DM^**1**^, ***N*** = 27,229T2DM, ***N*** = 4186***N***%***N***%**T-stage,*n*(%)** T1a6422.41463.5 T1b3311.2902.2 T1c13,28848.8164039.2 T2799929.4132831.7 T3359313.271317.0 T46172.31202.9 T0, Tx, Missing7592.81493.6**N-stage,*n*(%)** N0911233.5135532.4 N113464.92235.3 Nx, Missing16,77161.6260862.3**M-stage,*n*(%)** M024,78191.0369088.2 M124238.949311.8 Missing250.130.1**PSA,*n*(%)** PSA \< 4352612.93889.3 4 ≤ PSA \< 1012,37345.4161338.5 10 ≤ PSA \< 20475017.487420.9 20 ≤ PSA \< 50294510.855513.3 50 ≤ PSA \< 10011434.22636.3 PSA ≥ 10024929.249311.8**Gleason Grade Group**^**2**^**,*n*(%)** Grade group 110,15237.3115227.5 Grade group 2718326.4105625.2 Grade group 3349612.864515.4 Grade group 423978.847011.2 Grade group 5325311.971517.1 Missing7482.71483.5Numbers may not add up to 100% due to rounding^2^ Gleason grade group 1 = Gleason Score ≤ 6, Grade group 2 = Gleason Score 3 + 4 = 7, Grade group 3 = Gleason Score 4 + 3 = 7, Grade group 4 = Gleason Score 4 + 4, 3 + 5, 5 + 3 = 8, Grade group 5 = Gleason Score 9 and 10*Abbreviations*: *N* number, *T2DM* type 2 diabetes mellitus, *PSA* Prostate-Specific Antigen

The association of duration of T2DM and antidiabetic medications with PCa risk {#Sec9}
------------------------------------------------------------------------------

Overall, a decreased risk of PCa was observed for men with T2DM (OR: 0.81, 95% CI: 0.78--0.84), as compared to men without T2DM.

There was a consistent reduction of PCa risk over all durations of T2DM, except for men who were diagnosed of T2DM less than 1 year prior to PCa diagnosis. We found a 19% reduction in risk of PCa among men with T2DM for ≥1 year and \< 5 years and a 27% reduction in risk of PCa for men with pre-existing T2DM for at least 20 years as compared to men without T2DM (Table [3](#Tab3){ref-type="table"}). Men on insulin, high-and low-dose metformin, and SU showed a persistently decreased risk of PCa over all durations (Table [3](#Tab3){ref-type="table"}). Table 3Odds ratios and 95% CIs for risk of prostate cancer according to type 2 diabetes mellitus (T2DM) status and T2DM medicationsDependent variablesControlsCasesModel 1^**1**^Model 2^**2**^***N*** = 154,812***N*** = 31,415OR95% CIOR95% CI**T2DM** no DM129,84727,229RefRef T2DM24,96541860.80(0.77--0.83)0.81(0.78--0.84)**Duration of T2DM (years)** no DM129,84727,229RefRef  \< 113063071.12(0.99--1.27)1.15(1.01--1.30) 1 - \< 559839900.79(0.74--0.84)0.81(0.75--0.86) 5 - \< 10686211440.79(0.74--0.85)0.81(0.76--0.86) 10 - \< 20772412690.78(0.73--0.83)0.79(0.75--0.84) 2030904760.73(0.66--0.81)0.73(0.67--0.81)**Duration of Insulin (years)** no DM129,84727,229RefRef 0.5 - \< 323703350.67(0.59--0.75)0.68(0.60--0.76) 3 - \< 514982080.67(0.58--0.77)0.69(0.60--0.80) 543236450.71(0.65--0.77)0.72(0.66--0.79) Missing16,7742998**Duration of high-dose Metformin (years)** no DM129,84727,229RefRef 0.5 - \< 3633910100.76(0.71--0.82)0.77(0.72--0.83) 3 - \< 524504100.80(0.72--0.90)0.82(0.74--0.91) 521173760.86(0.77--0.96)0.87(0.78--0.98) Missing14,0592390**Duration of low-dose Metformin (years)** no DM129,84727,229RefRef 0.5 - \< 310,06915880.75(0.71--0.80)0.77(0.72--0.81) 3 - \< 539266630.80(0.74--0.87)0.82(0.75--0.89) 519183430.85(0.76--0.96)0.87(0.77--0.97) Missing90521592**Duration of SU (years)** no DM129,84727,229RefRef 0.5 - \< 326043690.68(0.61--0.76)0.68(0.61--0.76) 3 - \< 514022160.72(0.62--0.83)0.72(0.62--0.83) 519032930.74(0.66--0.84)0.76(0.67--0.86) Missing19,0563308^1^ Crude; ^2^ adjusted for CCI, education level, civil status and the age at year of PCa onset*Abbreviations*: *OR* odds ratio, *95% CI* 95% confidence interval, *PCa* prostate cancer, *T2DM* type 2 diabetes mellitus, *SU* sulfonylurea

The association of duration of T2DM and antidiabetic medications with PCa risk categories {#Sec10}
-----------------------------------------------------------------------------------------

There was a decreased risk of low- and intermediate-risk PCa for men with T2DM, as compared to men without T2DM (Table [4](#Tab4){ref-type="table"}). The decreased risk persisted over time, with the largest reduction found for men whose duration of T2DM was 10--20 years in the low-risk category and over 20 years in intermediate-risk category. However, no association was found for the high-risk category. Table 4Association of T2DM medications with risk categories of prostate cancer 1Low-risk categoryIntermediate-risk groupHigh-risk group 2Controls (N)Cases (***N***)OR95% CIControls (***N***)Cases (***N***)OR95% CIControls (***N***)Cases (***N***)OR95% CI**T2DM** no DM36,2477781Ref43,6919201Ref46,5499563Ref T2DM58987840.65(0.66--0.70)828013550.8(0.75--0.85)10,08419100.92(0.87--0.97)**Duration of T2DM (years)** no DM36,2477781Ref43,6919201Ref46,5499563Ref  \< 1320630.98(0.75--1.29)4471111.23(0.99--1.51)5071261.21(0.99--1.47) 1 - \< 516002170.66(0.57--0.76)20213310.81(0.72--0.91)21844030.9(0.81--1.01) 5 - \< 1016762160.63(0.54--0.72)22923790.8(0.72--0.90)27105070.91(0.82--1.00) 10 - \< 2017262160.61(0.53--0.71)25204010.78(0.70--0.87)32726110.9(0.83--0.99) 20576720.62(0.48--0.79)10001330.65(0.54--0.78)14112630.88(0.77--1.01)**Duration of Insulin (years)** no DM36,2477781Ref43,6919201Ref46,5499563Ref 0.5 - \< 3587490.42(0.31--0.56)7511130.76(0.62--0.94)9761600.78(0.65--0.92) 3 - \< 5369370.53(0.38--0.75)506570.57(0.43--0.76)5741010.86(0.70--1.10) 5908980.55(0.44--0.68)14701960.65(0.56--0.76)18293390.89(0.79--1.00) Missing4034600555398967051310**Duration of high-dose Metformin (years)** no DM36,2477781Ref43,6919201Ref46,5499563Ref 0.5 - \< 316092070.63(0.54--0.73)21383360.77(0.68--0.86)24184350.87(0.78--0.97) 3 - \< 5612640.52(0.40--0.68)8551470.85(0.71--1.01)9241850.98(0.83--1.15) 5530660.61(0.47--0.79)7711230.77(0.64--0.94)7511761.17(0.99--1.38) Missing3147447451674959911114**Duration of low-dose Metformin (years)** no DM36,2477781Ref43,6919201Ref46,5499563Ref 0.5 - \< 326023140.6(0.53--0.68)34705130.73(0.66--0.80)37187090.92(0.85--1.00) 3 - \< 59201190.63(0.52--0.77)12592380.9(0.78--1.04)16342870.86(0.75--0.98) 5401560.67(0.51--0.89)6071030.84(0.68--1.03)8441731(0.84--1.18) Missing1975129729445013888741**Duration of SU (years)** no DM36,2477781Ref43,6919201Ref46,5499563Ref 0.5 - \< 3593640.53(0.41--0.69)8811320.73(0.61--0.89)10591700.76(0.64--0.90) 3 - \< 5342420.6(0.43--0.83)452670.7(0.54--0.91)567980.79(0.64--0.99) 5367480.68(0.50--0.92)602820.66(0.52--0.84)8821540.85(0.72--1.02) Missing459663063451074757614881 The results were adjusted for CCI, education level, civil status and the age at year of PCa onset2 We combined high risk, reginal metastases, and distant metastases into high-risk category group

With respect to duration of antidiabetic medications, the reduction in PCa risk was again clearest for low and intermediate-risk PCa. For those taking insulin, there was a decreased risk of low-risk PCa (OR: 0.42, 95% CI: 0.31--0.56) at 0.5--3 years (Table [4](#Tab4){ref-type="table"}). A similar association was seen for men taking high- and low-dose metformin and SU. For the intermediate-risk PCa category, there was a decreased risk with all durations of different antidiabetic medications. In contrast, no association was observed in high-risk PCa category (Table [4](#Tab4){ref-type="table"}). No clear associations were observed inthe subgroup analysis,inwhich the high-risk category was further divided into: high-risk, regional metastases, and distant metastases (Table [5](#Tab5){ref-type="table"}). Table 5Association of T2DM and antidiabetic medications with high-risk, regional metastases and distant metastases of prostate cancer 1High risk 2Regional metastasesDistant metastasesControls (***N***)Cases (***N***)OR95% CIControls (***N***)Cases (***N***)OR95% CIControls (***N***)Cases (***N***)OR95% CI**T2DM** no DM24,7465081Ref67721398Ref15,0313084Ref T2DM533310110.93(0.87--1.00)15192820.9(0.78--1.04)32326170.91(0.82--1.00)**Duration of T2DM (years)** no DM24,7465081Ref67721398Ref15,0313084Ref  \< 1257671.28(0.97--1.68)92150.76(0.43--1.35)158441.33(0.95--1.87) 1 - \< 511222240.99(0.85--1.14)350620.87(0.66--1.15)7121170.8(0.65--0.97) 5 - \< 1014532810.95(0.83--1.08)396680.84(0.64--1.09)8161580.87(0.73--1.04) 10 - \< 2017273160.9(0.80--1.02)467940.97(0.77--1.22)10782010.89(0.76--1.04) 207741230.77(0.63--0.94)214430.96(0.69--1.35)423971.06(0.84--1.32)**Duration of Insulin (years)** no DM24,7465081Ref67721398Ref15,0313084Ref 0.5 - \< 3509800.77(0.60--0.98)150160.52(0.31--0.88)317640.9(0.68--1.19) 3 - \< 5291460.85(0.63--1.16)86170.97(0.57--1.65)197350.83(0.58--1.20) 59711690.86(0.72--1.01)270500.88(0.64--1.21)5881200.96(0.78--1.18) Missing356271310131992130398**Duration of high-dose Metformin (years)** no DM24,7465081Ref67721398Ref15,0313084Ref 0.5 - \< 312902350.89(0.77--1.03)367660.87(0.66--1.15)7611340.84(0.69--1.02) 3 - \< 5508970.96(0.77--1.20)125331.23(0.82--1.83)291550.89(0.67--1.20) 5408951.19(0.94--1.50)112230.96(0.61--1.52)231581.25(0.93--1.68) Missing31275849151601949370**Duration of low-dose Metformin (years)** no DM24,7465081Ref67721398Ref15,0313084Ref 0.5 - \< 319663850.97(0.86--1.09)5521010.89(0.71--1.12)12002230.86(0.74--1.00) 3 - \< 58911520.85(0.72--1.02)228481(0.73--1.38)515870.81(0.64--1.02) 5428860.97(0.76--1.23)124331.44(0.97--2.15)292540.87(0.65--1.17) Missing20483886151001225253**Duration of SU (years)** no DM24,7465081Ref67721398Ref15,0313084Ref 0.5 - \< 3559810.7(0.55--0.88)151290.89(0.58--1.36)349600.83(0.62--1.09) 3 - \< 5302540.85(0.63--1.15)78150.95(0.53--1.70)187290.65(0.43--0.98) 5469690.74(0.57--0.96)128220.81(0.51--1.28)285631.07(0.81--1.42) Missing4003807116221624114651 The results were adjusted for CCI, education level, civil status and the age at year of PCa onset2 Cases in "high risk" only refer to PCa men at T3a or T4 stage, whose PSA ≥ 20 ng/ml or Gleason Score ≥ 8, without regional metastases and distant metastases

Discussion {#Sec11}
==========

In this nationwide, population-based case-control study, we observed that men with T2DM had a decreased risk of PCa for any duration of T2DM, as well as any exposure time to all types of antidiabetic medication. The reduction in risk was strongest for low- and intermediate- risk PCa, whereas there was no decrease for high-risk PCa.

Duration of T2DM medication {#Sec12}
---------------------------

We found a consistent reduction of PCa risk over all durations of T2DM, which supports previous studies \[[@CR4], [@CR23]--[@CR25]\]. This study provides new observations regarding duration of antidiabetic drugs, including metformin, insulin and SU. The results demonstrate a persistently decreased risk of PCa for all anti-diabetic medications and durations. One possible explanation for this observation is that metformin and insulin are thought to reduce the activity of mTOR, which blocks progression of the cell cycle and cancer growth \[[@CR26], [@CR27]\]. For example, Pircher et al. conducted a study exploring antidiabetic drugs that influence molecular mechanisms in prostate cancer and showed that insulin use significantly decreased active mTOR in cancer tissue \[[@CR26]\]. In addition, they found an AMPK and AKT independent regulation of the mTOR pathway, as there were no differences in pAKT levels among treatment groups (insulin and metformin groups) \[[@CR26]\]. Hence, medication that can attenuate mTOR activity with subsequent blockade of cell cycle progression, can potentially also block the progression of the prostate cell cycle and cancer growth \[[@CR28]\]. However, some observational studies have shown no protective effect of metformin and insulin on PCa risk \[[@CR14], [@CR29]--[@CR31]\]. These studies did not take selection bias and confounding into account. Studies examining the impact of SU on PCa risk have provided inconsistent results \[[@CR11], [@CR32], [@CR33]\]. No previous study has examined SU separately from other antidiabetic drugs or examined the impact of its duration on PCa risk, as we have here.

Risk categories of PCa {#Sec13}
----------------------

We found a consistently stronger inverse association of duration of T2DM and antidiabetic medications with risk of low and intermediate-risk PCa. This association was not observed for high-risk PCa, regional and distant metastatic PCa. These results are consistent with previous large population-based studies \[[@CR23], [@CR33], [@CR34]\], which concluded that neither T2DM nor antidiabetic medications were associated with a reduction in risk of aggressive PCa. Conversely, some studies \[[@CR35]--[@CR38]\] have found that T2DM is associated with increased risk of high-grade PCa. The biological mechanism behind this remains unclear \[[@CR14]\].

It is essential to consider detection bias when evaluating the association of T2DM and antidiabetic treatments with different risk categories of PCa. Early detection of PCa depends on PSA testing and subsequent biopsy of the prostate. PSA levels have been shown to be lower in T2DM patients than in non-diabetic men \[[@CR39]\]. Therefore, PSA is less sensitive to detect early-stage PCa in men with T2DM. Prostate size among PCa men with T2DM has been reported to be larger than in men without T2DM, which may affect biopsy results \[[@CR40]\]. A larger prostate may dilute the cancer cells, which may cause a decrease in the probability of the detection of small indolent cancers in the low-risk category group using biopsy \[[@CR39]\]. These two observations may affect PCa detection at an early stage, which may partially explain the decreased risk of low-risk PCa among men with T2DM. Men with T2DM who developed into PCa are therefore more likely to be diagnosed at a more advanced stage.

Strengths/limitations {#Sec14}
---------------------

The strength of this study is the use of data from a national-wide cohort in Sweden, which has been linked to other national high-quality registers and demographic databases including the Longitudinal integrated database for health insurance and labour market studies, the National Diabetes Register and the National Prescribed Drug Register. Since previous PCBaSe studies were performed, there has been a substantial improvement in the completeness of the National Diabetes Register \[[@CR41]\], which make the data in this study more representative. We also included information from the Prescribed Drug Registry, which comprises all out-patients filled prescription data since July 2005 \[[@CR41]\]. We were also able to investigate the association of different anti-diabetic medications including high-dose and low-dose metformin with PCa risk using detailed prescription data from the National Prescribed Drug Register. Thirdly, our study had a longer follow-up (8.5 years) than other studies where median follow-up was 5--7 years \[[@CR14], [@CR29], [@CR42]\]. A limitation of our study is that there was insufficient power to investigate associations of exposure times to antidiabetic medications with low-risk/ intermediate-risk/ high-risk PCa given the smaller number of men with PCa in these specific risk categories. Secondly, our study may be prone to residual confounding (e.g., family history of T2DM and PCa), although we obtained detailed information of participants' socio-economic status from the Longitudinal integrated database for health insurance and labour market studies database. Thirdly, approximately 6% of participants had missing data on the date of T2DM diagnosis and registration in the National Diabetes Register registry. We used duration of antidiabetic medications in the National Prescribed Drug Register to replace these missing values, which may result in a shorter interval between T2DM diagnosis and PCa diagnosis.

Conclusion {#Sec15}
==========

There was a persistent decreased risk of PCa across all anti-diabetic medications studied and across all durations of T2DM. This association was strongest for risk of low- and intermediate risk PCa and not observed for high-risk PCa. Given the prevalence of T2DM worldwide, it is important to note that T2DM and its medication may protect some men from PCa, though not necessarily from developing high risk disease. However, the interplay between T2DM and PCa warrants further study.

PCa

:   Prostate cancer

PSA

:   Prostate-Specific Antigen

T2DM

:   Type 2 diabetes mellitus

SU

:   Sulfonylurea

CCI

:   Charlson Comorbidity Index

OR

:   Odds ratio

95% CI

:   95% confidence interval

PCBaSe

:   Prostate Cancer data Base Sweden
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